SANOFI

Sanofi India Share Price

₹5,390.00 -4.65 (-0.09%)

22 Jan, 2025 12:10

SIP TrendupStart SIP in SANOFI

Start SIP

Performance

  • Low
  • ₹5,362
  • High
  • ₹5,426
  • 52 Week Low
  • ₹5,362
  • 52 Week High
  • ₹10,525
  • Open Price₹5,400
  • Previous Close₹5,395
  • Volume4,997

Investment Returns

  • Over 1 Month -12.36%
  • Over 3 Month -19.34%
  • Over 6 Month -14.95%
  • Over 1 Year -35.58%
SIP Lightning

Smart Investing Starts Here Start SIP with Sanofi India for Steady Growth!

Invest Now

Sanofi India Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 27
  • PEG Ratio
  • -22.6
  • Market Cap Cr
  • 12,414
  • P/B Ratio
  • 16.2
  • Average True Range
  • 151.64
  • EPS
  • 183.05
  • Dividend Yield
  • 3.1
  • MACD Signal
  • -160.01
  • RSI
  • 16.7
  • MFI
  • 14.74

Sanofi India Financials

Sanofi India Technicals

EMA & SMA

Current Price
₹5,390.00
-4.65 (-0.09%)
pointer
  • stock-down_img
  • Bearish Moving Average 16
  • stock-up_img
  • Bullish Moving Average 0
  • 20 Day
  • ₹5,776.94
  • 50 Day
  • ₹6,067.51
  • 100 Day
  • ₹6,386.16
  • 200 Day
  • ₹6,788.39

Resistance and Support

5451.3 Pivot Speed
  • R3 5,706.85
  • R2 5,640.55
  • R1 5,517.60
  • S1 5,328.35
  • S2 5,262.05
  • S3 5,139.10

What's your outlook on Sanofi India?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Sanofi India Ltd. is a pharmaceutical company offering a wide range of medicines and vaccines. It focuses on diabetes, cardiovascular, rare diseases, and consumer healthcare, providing solutions to improve health outcomes across India.

Sanofi India Ltd has an operating revenue of Rs. 2,413.80 Cr. on a trailing 12-month basis. An annual revenue growth of 3% is not great, Pre-tax margin of 30% is great, ROE of 59% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 29 which is a POOR score indicating inconsistency in earnings, a RS Rating of 31 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 55 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Sanofi India Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-07 Quarterly Results
2024-07-26 Quarterly Results
2024-05-13 Quarterly Results
2024-02-23 Audited Results & Dividend
2023-11-08 Quarterly Results
Date Purpose Remarks
2024-05-03 FINAL Rs.117.00 per share(1170%)Final Dividend
2024-03-07 INTERIM Rs.50.00 per share(500%)Interim Dividend
2022-08-08 SPECIAL Rs.193.00 per share (1930%) One Time Special Interim Dividend
View More

Sanofi India F&O

Sanofi India Shareholding Pattern

60.4%
11.05%
11.65%
5.64%
0%
8.33%
2.93%

About Sanofi India

  • NSE Symbol
  • SANOFI
  • BSE Symbol
  • 500674
  • Managing Director
  • Mr. Rodolfo Hrosz
  • ISIN
  • INE058A01010

Similar Stocks to Sanofi India

Sanofi India FAQs

Sanofi India share price is ₹5,390 As on 22 January, 2025 | 11:56

The Market Cap of Sanofi India is ₹12413.5 Cr As on 22 January, 2025 | 11:56

The P/E ratio of Sanofi India is 27 As on 22 January, 2025 | 11:56

The PB ratio of Sanofi India is 16.2 As on 22 January, 2025 | 11:56

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23